Nat Genet. 2023 Sep;55(9):1471-1482. doi: 10.1038/s41588-023-01485-w. Epub 2023 Aug 31.
Epilepsy is a highly heritable disorder affecting over 50 million people worldwide, of which about one-third are resistant to current treatments. Here we report a multi-ancestry genome-wide association study including 29,944 cases, stratified into three broad categories and seven subtypes of epilepsy, and 52,538 controls. We identify 26 genome-wide significant loci, 19 of which are specific to genetic generalized epilepsy (GGE). We implicate 29 likely causal genes underlying these 26 loci. SNP-based heritability analyses show that common variants explain between 39.6% and 90% of genetic risk for GGE and its subtypes. Subtype analysis revealed markedly different genetic architectures between focal and generalized epilepsies. Gene-set analyses of GGE signals implicate synaptic processes in both excitatory and inhibitory neurons in the brain. Prioritized candidate genes overlap with monogenic epilepsy genes and with targets of current antiseizure medications. Finally, we leverage our results to identify alternate drugs with predicted efficacy if repurposed for epilepsy treatment.
癫痫是一种高度遗传性疾病,影响着全球超过 5000 万人,其中约三分之一的患者对现有治疗方法有抗药性。在这里,我们报告了一项多血统全基因组关联研究,其中包括 29944 例病例,分为三大类和七种癫痫亚型,并纳入了 52538 名对照者。我们确定了 26 个全基因组显著位点,其中 19 个与遗传全面性癫痫(GGE)有关。我们确定了 29 个可能导致这些 26 个位点的因果基因。基于 SNP 的遗传率分析表明,常见变异解释了 GGE 及其亚型 39.6%至 90%的遗传风险。亚型分析表明,局灶性和全面性癫痫之间的遗传结构明显不同。GGE 信号的基因集分析表明,大脑中兴奋性和抑制性神经元的突触过程都涉及其中。优先考虑的候选基因与单基因癫痫基因和当前抗癫痫药物的靶点重叠。最后,我们利用研究结果来确定如果重新用于癫痫治疗,具有预测疗效的替代药物。